Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.

Sisa, Ivan; Noblecilla, Estefania; Orozco, Fadya

Sisa, Ivan; Noblecilla, Estefania; Orozco, Fadya.

Sisa I; College of Health Sciences, Universidad San Francisco de Quito, Quito 170901, Ecuador. Electronic address: isisa@usfq.edu.ec.
Noblecilla E; Institutional Review Board, Universidad San Francisco de Quito, Quito 170901, Ecuador.
Orozco F; College of Health Sciences, Universidad San Francisco de Quito, Quito 170901, Ecuador.

Lancet ; 397(10277): 878, 2021 03 06.

Article in English | MEDLINE | ID: covidwho-1174541

Subject(s)

COVID-19 Vaccines; Developing Countries; Randomized Controlled Trials as Topic/ethics; COVID-19; COVID-19 Vaccines/supply & distribution; Humans; Placebos; Randomized Controlled Trials as Topic/economics; Risk Assessment; SARS-CoV-2; Therapeutic Equipoise

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Developing Countries / COVID-19 Vaccines Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google